Literature DB >> 15651903

Switching between second-generation antipsychotics: why and how?

Monika Edlinger1, Susanne Baumgartner, Nadja Eltanaihi-Furtmüller, Martina Hummer, W Wolfgang Fleischhacker.   

Abstract

The introduction of second-generation antipsychotics represents an important advance in the treatment of schizophrenia. Although these drugs are generally very effective, not all patients respond in the same way. Partial response with persistent positive and negative symptoms and residual symptoms may force physicians to change antipsychotic medication. As more and more second-generation antipsychotics are introduced, the need for practical guidelines on switching these medications becomes increasingly important. In this article we provide a short summary of the second-generation antipsychotics, focusing on efficacy, adverse effect profile and safety. Indications for switching antipsychotic medication are outlined, as well as recommendations when switching is disadvantageous. Three basic switching strategies (abrupt, gradual and overlapping switching) and their potential risks and benefits are described. We review the available evidence concerning techniques, problems and consequences when switching from one second-generation antipsychotic agent to another and discuss potential difficulties.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15651903     DOI: 10.2165/00023210-200519010-00003

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  93 in total

1.  Association of olanzapine-induced weight gain with an increase in body fat.

Authors:  U Eder; B Mangweth; C Ebenbichler; E Weiss; A Hofer; M Hummer; G Kemmler; M Lechleitner; W W Fleischhacker
Journal:  Am J Psychiatry       Date:  2001-10       Impact factor: 18.112

2.  Cautions in the clozapine-to-risperidone switch.

Authors:  S Gupta; D G Daniel
Journal:  Ann Clin Psychiatry       Date:  1995-09       Impact factor: 1.567

3.  Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.

Authors:  M R Dossenbach; P Kratky; M Schneidman; S L Grundy; S Metcalfe; G D Tollefson; R H Belmaker
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

Review 4.  Aripiprazole: profile on efficacy and safety.

Authors:  Paul J Goodnick; Jason M Jerry
Journal:  Expert Opin Pharmacother       Date:  2002-12       Impact factor: 3.889

Review 5.  Tolerability of atypical antipsychotics.

Authors:  C Stanniland; D Taylor
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

6.  Olanzapine increases weight and serum triglyceride levels.

Authors:  D N Osser; D M Najarian; R L Dufresne
Journal:  J Clin Psychiatry       Date:  1999-11       Impact factor: 4.384

Review 7.  Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.

Authors:  A H Glassman; J T Bigger
Journal:  Am J Psychiatry       Date:  2001-11       Impact factor: 18.112

Review 8.  Clozapine: a comparison with other novel antipsychotics.

Authors:  W W Fleischhacker
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

9.  Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific.

Authors:  Chien-Te Lee; Bernardo Jorge L Conde; Mahmud Mazlan; Taweesin Visanuyothin; Adrian Wang; Michael M C Wong; Daniel J Walker; Suraja M Roychowdhury; Huei Wang; Pierre V Tran
Journal:  J Clin Psychiatry       Date:  2002-07       Impact factor: 4.384

10.  Suicide attempts among patients with psychosis in a Chinese rural community.

Authors:  Mao-Sheng Ran; Cecilia Lai-Wan Chan; Meng-Ze Xiang; Qiu-Hua Wu
Journal:  Acta Psychiatr Scand       Date:  2003-06       Impact factor: 6.392

View more
  7 in total

Review 1.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

Review 2.  Immediate vs Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-analysis.

Authors:  Hiroyoshi Takeuchi; Navot Kantor; Hiroyuki Uchida; Takefumi Suzuki; Gary Remington
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

3.  Atypical Treatment Switches in Schizophrenia Patients: Drivers and Associated Outcomes.

Authors:  Rezaul Khandker; Jason Shepherd; Farid Chekani; Zaina Qureshi; Hollie Bailey; Mia Berry; Jack Wright; Lucy Massey
Journal:  Neuropsychiatr Dis Treat       Date:  2022-05-18       Impact factor: 2.989

4.  Switching Antipsychotic Medications in People with Schizophrenia: A 4-Year Naturalistic Study.

Authors:  Giammarco Cascino; Rossella Ceres; Alessio Maria Monteleone; Paola Bucci; Giulia Maria Giordano; Silvana Galderisi; Palmiero Monteleone
Journal:  J Clin Med       Date:  2022-10-10       Impact factor: 4.964

5.  Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study.

Authors:  Jihyung Hong; Diego Novick; Roberto Brugnoli; Jamie Karagianis; Martin Dossenbach; Josep Maria Haro
Journal:  BMC Psychiatry       Date:  2012-12-04       Impact factor: 3.630

6.  Evaluation of patients on sertindole treatment after failure of other antipsychotics: a retrospective analysis.

Authors:  Jean-Michel Azorin; Susana Murteira; Karina Hansen; Mondher Toumi
Journal:  BMC Psychiatry       Date:  2008-03-14       Impact factor: 3.630

7.  Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice.

Authors:  Joseph Peuskens; Gabriel Rubio; Andreas Schreiner
Journal:  Ann Gen Psychiatry       Date:  2014-04-01       Impact factor: 3.455

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.